It’s been just six months since Zevra Therapeutics scored an FDA nod for Miplyffa as the first approved treatment for the rare lysosomal storage disorder Niemann-Pick disease type C (NPC), but ...

Zevra Therapeutics (ZVRA) announced the closing of the sale of its Rare Pediatric Disease Priority Review Voucher for gross proceeds of $150M.

Orphazyme later sold the drug’s rights to KemPharma, which rebranded it as Zevra. According to GlobalData’s Pharma ...

CELEBRATION, Fla., March 31, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (Nasdaq:GS ZVRA) (“Zevra,” or the “Company”), a commercial-stage company ...

Confirms Receipt of Two Director Nominees from Daniel J. ManglessStockholders Are Not Required to Take Action at This TimeCELEBRATION, Fla., ...

Stockholders Are Not Required to Take Action at This Time CELEBRATION, Fla., March 31, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (Nasdaq:GS ZVRA) (“Zevra,” or the“Company”), a ...